Acute promyelocytic leukemia (APL) comprises 5–10% of AML cases and is characterized by the presence of a fusion between the transcription factor promyelocytic leukemia (PML) and the retinoic acid receptor α (RARA) genes [19, 20]. The gene discussed is RARA; the disease is acute myeloid leukemia.